



Drug List Updates

July 2018

TRADE NAME (generic name) or generic name	Brand/Generic	Description of Change
BELSOMRA (suvorexant tab 10 mg)	Brand	Addition
BELSOMRA (suvorexant tab 15 mg)	Brand	Addition
BELSOMRA (suvorexant tab 20 mg)	Brand	Addition
BELSOMRA (suvorexant tab 5 mg)	Brand	Addition
EMEND (aprepitant capsule 125 mg)	Brand	Removal, generics available
EMEND (aprepitant capsule 40 mg)	Brand	Removal, generics available
EXJADE (deferasirox tab for oral susp 125 mg)	Brand	Addition
EXJADE (deferasirox tab for oral susp 250 mg)	Brand	Addition
EXJADE (deferasirox tab for oral susp 500 mg)	Brand	Addition
GLYXAMBI (empagliflozin-linagliptin tab 10-5 mg)	Brand	Addition
GLYXAMBI (empagliflozin-linagliptin tab 25-5 mg)	Brand	Addition
HEMLIBRA (emicizumab-kxwh subcutaneous soln 105 mg/0.7 ml (150 mg/ml))	Brand	Addition
HEMLIBRA (emicizumab-kxwh subcutaneous soln 150 mg/ml)	Brand	Addition
HEMLIBRA (emicizumab-kxwh subcutaneous soln 30 mg/ml)	Brand	Addition
HEMLIBRA (emicizumab-kxwh subcutaneous soln 60 mg/0.4 ml (150 mg/ml))	Brand	Addition
JADENU (deferasirox tab 180 mg)	Brand	Addition
JADENU (deferasirox tab 360 mg)	Brand	Addition
JADENU (deferasirox tab 90 mg)	Brand	Addition
KADIAN (morphine sulfate cap er 24hr 200 mg)	Brand	Removal
KADIAN (morphine sulfate cap er 24hr 40 mg)	Brand	Removal
OZEMPIC (semaglutide soln pen-inj 0.25 or 0.5 mg/dose (2 mg/1.5 ml))	Brand	Addition
OZEMPIC (semaglutide soln pen-inj 1 mg/dose (2 mg/1.5 ml))	Brand	Addition
PATADAY (olopatadine hcl ophth soln 0.2% (base equivalent))	Brand	Removal, generics available
REBINYN (coagulation factor ix recomb glycopegylated for inj 1000 unt)	Brand	Addition
REBINYN (coagulation factor ix recomb glycopegylated for inj 2000 unt)	Brand	Addition
REBINYN (coagulation factor ix recomb glycopegylated for inj 500 unt)	Brand	Addition
REYATAZ (atazanavir sulfate cap 150 mg (base equiv))	Brand	Removal, generics available
REYATAZ (atazanavir sulfate cap 200 mg (base equiv))	Brand	Removal, generics available
REYATAZ (atazanavir sulfate cap 300 mg (base equiv))	Brand	Removal, generics available
SUSTIVA (efavirenz cap 200 mg)	Brand	Removal, generics available
SUSTIVA (efavirenz cap 50 mg)	Brand	Removal, generics available
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol aepb 100-62.5-25 mcg/inh)	Brand	Addition
VIREAD (tenofovir disoproxil fumarate tab 300 mg)	Brand	Removal, generics available
ZENPEP (pancrelipase (lip-prot-amyl) dr cap 25000-79000-105000 unit)	Brand	Addition
ZENPEP (pancrelipase (lip-prot-amyl) dr cap 5000-17000-24000 unit)	Brand	Addition

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent Licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Illinois (BCBSIL) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.